Press Releases

Date	Title and Summary	View
Toggle Summary Mar 02, 2018	Zosano Pharma Announces Issuance of New U.S. Patent Covering M207 as an Acute Treatment for Migraine Patent extends proprietary position of M207 to 2037	View HTML Zosano Pharma Announces Issuance of New U.S. Patent Covering M207 as an Acute Treatment for Migraine 17.6 KB
Toggle Summary Jan 25, 2018	Zosano Announces Results of Special Meeting of Stockholders and 1-for-20 Reverse Stock Split Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on January 26, 2018	View HTML Zosano Announces Results of Special Meeting of Stockholders and 1-for-20 Reverse Stock Split 20.3 KB
Toggle Summary Jan 03, 2018	Zosano Pharma Announces Notice of Allowance for a U.S. Patent Application Covering M207 as an Acute Treatment for Migraine Issuance Will Extend Patent Life of M207 to 2037	View HTML Zosano Pharma Announces Notice of Allowance for a U.S. Patent Application Covering M207 as an Acute Treatment for Migraine 18.4 KB
Toggle Summary Dec 15, 2017	Zosano Announces Resignation of Bruce Steel from Board of Directors FREMONT, Calif., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, announced today	View HTML Zosano Announces Resignation of Bruce Steel from Board of Directors 15.7 KB
Toggle Summary Nov 15, 2017	Zosano Pharma to Present at 29th Annual Piper Jaffray Healthcare Conference FREMONT, Calif., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray	View HTML Zosano Pharma to Present at 29th Annual Piper Jaffray Healthcare Conference 16.8 KB
Toggle Summary Nov 09, 2017	Zosano Pharma Reports Third Quarter 2017 Financial Results and Operational Update First patient enrolled in long term safety study in November 2017 Phase 2/3 data presented at International Headache Society in September Clinical results published in two leading scientific journals Access to capital expanded to fund Long-term Safety Study FREMONT, Calif., Nov.	View HTML Zosano Pharma Reports Third Quarter 2017 Financial Results and Operational Update 89.4 KB
Toggle Summary Nov 08, 2017	Zosano Pharma Announces Initiation of Long-Term Safety Study for M207 as an Acute Treatment of Migraine FREMONT, Calif., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray	View HTML Zosano Pharma Announces Initiation of Long-Term Safety Study for M207 as an Acute Treatment of Migraine 18.8 KB
Toggle Summary Nov 01, 2017	Zosano Pharma to Host Conference Call on Third Quarter 2017 Financial Results and Provide Operational Update FREMONT, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray (ADAM) technology, today	View HTML Zosano Pharma to Host Conference Call on Third Quarter 2017 Financial Results and Provide Operational Update 15 KB
Toggle Summary Oct 20, 2017	Zosano Enters into Common Stock Purchase Agreement with Lincoln Park Capital FREMONT, Calif., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, announced today	View HTML Zosano Enters into Common Stock Purchase Agreement with Lincoln Park Capital 18.7 KB
Toggle Summary Oct 12, 2017	Zosano Announces Publication of Pivotal Data of ADAM Zolmitriptan for the Acute Treatment of Migraine in Cephalalgia FREMONT, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray	View HTML Zosano Announces Publication of Pivotal Data of ADAM Zolmitriptan for the Acute Treatment of Migraine in Cephalalgia 27.3 KB